Header Logo

Connection

AMY COURTNEY to Natural Killer T-Cells

Back to Details
This is a "connection" page, showing publications AMY COURTNEY has written about Natural Killer T-Cells.
AMY COURTNEY
Connection Strength
2.725
Natural Killer T-Cells
  1. Natural killer T cells and other innate-like T?lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood. 2023 02 23; 141(8):869-876.
    View in: PubMed
    Score: 0.764
  2. Intranasal but not intravenous delivery of the adjuvant a-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Eur J Immunol. 2011 Nov; 41(11):3312-22.
    View in: PubMed
    Score: 0.346
  3. PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector Function. Cancer Immunol Res. 2025 Apr 02; 13(4):577-590.
    View in: PubMed
    Score: 0.221
  4. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.
    View in: PubMed
    Score: 0.194
  5. LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells. Cancer Immunol Res. 2023 02 03; 11(2):171-183.
    View in: PubMed
    Score: 0.190
  6. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020 11; 26(11):1686-1690.
    View in: PubMed
    Score: 0.162
  7. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
    View in: PubMed
    Score: 0.150
  8. IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol. 2018 10 01; 201(7):2141-2153.
    View in: PubMed
    Score: 0.139
  9. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016 06 01; 126(6):2341-55.
    View in: PubMed
    Score: 0.119
  10. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014 Oct 30; 124(18):2824-33.
    View in: PubMed
    Score: 0.105
  11. C-Glycosphingolipids with an exo-methylene substituent: stereocontrolled synthesis and immunostimulation of mouse and human natural killer T lymphocytes. Chembiochem. 2012 Aug 13; 13(12):1733-7.
    View in: PubMed
    Score: 0.091
  12. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012 Jun; 122(6):2221-33.
    View in: PubMed
    Score: 0.090
  13. Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Vaccine. 2009 May 26; 27(25-26):3484-8.
    View in: PubMed
    Score: 0.072
  14. Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J Immunother Cancer. 2025 Jan 11; 13(1).
    View in: PubMed
    Score: 0.054
  15. Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res. 2014 Nov 01; 74(21):6260-70.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.